Biodexa Pharmaceuticals Plc (5MP0.SG)

0,8500 0,0000 (0,00 %) À la clôture : 08:18AM CEST

Biodexa Pharmaceuticals Plc

1 Caspian Point
Caspian Way
Cardiff CF10 4DQ
United Kingdom
44 29 2048 0180
https://www.biodexapharma.com

Secteur(s): 
Secteur d’activité: 
Employés à temps plein: 21

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Stephen A. Stamp	CEO, CFO, Company Secretary & Director	297,78k	S.O.	1962
Dr. Dmitry Zamoryakhin M.D.	Chief Scientific Officer & Chief Medical Officer	281,66k	S.O.	1980
Dr. Daniel Palmer MBA, Ph.D.	Vice President of Technology	S.O.	S.O.	S.O.
Ms. Nicola Tuckwell	VP & Head of Clinical Operations	S.O.	S.O.	S.O.
Steve Ellul	Chief Business Officer	S.O.	S.O.	S.O.
Ms. Fiona Sharp	Group Financial Controller	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en EUR.

Description

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Biodexa Pharmaceuticals Plc en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.